Iptacopan's orphan-drug status secured an established additional benefit and a substantial quality-of-life finding in Germany without a single comparator dossier argument.
PNH has no confirmed German prevalence data of its own. The DGHO's Onkopedia guideline extrapolates instead from British and French registries, landing on an estimated 16 cases per million and 1.3 new diagnoses per million annually. It states plainly that Germany-specific figures do not exist. Diagnosis runs on GPI-anchor flow cytometry: at least two GPI-anchored markers must show deficient or reduced expression across at least two cell lineages, typically granulocytes and reticulocytes. Two centres anchor the country's referral network. The German PNH-Register sits at Ulm's Institute for Clinical Transfusion Medicine and Immunogenetics; the West German Cancer Center at University Hospital Essen is the other. Both feed patients into the International PNH Registry, the same registry underpinning the long-term ravulizumab and eculizumab outcomes data.
Iptacopan's route to reimbursement skipped the standard AMNOG fight entirely. As an orphan-designated therapy, its additional benefit counted as established through EMA approval under §35a Absatz 1 Satz 11 SGB V. IQWiG never had to build a head-to-head dossier against anti-C5 therapy. The G-BA went further on 19 December 2024, finding a substantial (beträchtlich) additional benefit specifically on quality of life for patients switching from anti-C5 therapy. In March 2025 the G-BA also declined to require accompanying data collection, judging a parallel registry structure disproportionate given the one already in place. Crovalimab has no such shortcut: its dossier, submitted 12 September 2024, remains under active IQWiG assessment. Ravulizumab's only Germany-specific finding is narrower still. A March 2022 review of its pediatric indication found no additional benefit against eculizumab.
Approved and assessed PNH agents — Germany
| Drug (Brand / INN) | Mechanism | Company | EMA / G-BA Status | Key Evidence | AMNOG Outcome |
|---|---|---|---|---|---|
| Soliris (eculizumab) | Anti-C5 mAb IV q2w | AstraZeneca | EMA approved 2007; long-standing German anti-C5 incumbent | International PNH Registry — 49% relative survival benefit vs untreated (Terriou et al., Eur J Haematol 2023) | Pre-AMNOG-era launch; no Germany-specific comparator dossier identified |
| Ultomiris (ravulizumab) | Anti-C5 mAb IV q8w | AstraZeneca | EMA approved (adult); G-BA pediatric-indication Beschluss 18 Mar 2022 | HERCULES pivotal data; International PNH Registry 6-yr follow-up (Kulasekararaj et al., Ann Hematol 2025) | No added benefit vs eculizumab shown for the pediatric indication specifically |
| Fabhalta (iptacopan) | Oral Factor B inhibitor | Novartis | EMA approved 17 May 2024; G-BA Beschluss 19 Dec 2024 | Orphan-pathway benefit established through approval; QoL beträchtlich finding vs anti-C5 (pretreated patients) | Additional benefit established via §35a Abs.1 S.11 SGB V orphan pathway; AbD not required (Mar 2025) |
| Piasky (crovalimab) | Anti-C5 SC recycling mAb | Roche | Benefit dossier submitted 12 Sep 2024; IQWiG assessment in progress | COMMODORE 1 & 2 trial data | AMNOG outcome pending |
Sources: G-BA Nutzenbewertungsverfahren Iptacopan (Beschluss 19.12.2024); G-BA Nutzenbewertungsverfahren Ravulizumab pediatric PNH (Beschluss 18.03.2022); IQWiG Dossierbewertung Iptacopan (G24-16); G-BA Fachnews on the iptacopan AbD waiver; G-BA Crovalimab benefit dossier (submitted 12.09.2024); DGHO Onkopedia PNH guideline; Kulasekararaj et al., Ann Hematol 2025; Terriou et al., Eur J Haematol 2023; Orphanet German PNH-Register listing (Ulm).
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- §35a Abs.1 S.11 SGB V orphan pathway mechanics
- the 19 Dec 2024 G-BA Beschluss category (substantial/beträchtlich additional benefit on quality of life vs anti-C5)
- the March 2025 AbD-waiver decision and its rationale
Delivers
- German PNH-Register (Ulm) and International PNH Registry cross-enrollment
- flow cytometry diagnostic threshold requirements
- addressable-population sizing methodology when no confirmed national patient count exists
Delivers
- Crovalimab benefit-dossier timeline (submitted 12 Sept 2024) and assessment status
- ravulizumab's March 2022 pediatric-indication G-BA finding (no added benefit vs eculizumab)
- comparator-therapy precedent for future anti-C5 dossiers
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Why Germany has no confirmed PNH prevalence of its own, forcing Onkopedia to extrapolate 16 cases per million from UK and French registries
- How GPI-anchor flow cytometry diagnosis requires deficient expression of at least two markers across granulocytes and reticulocytes
- Why the §35a Abs.1 S.11 SGB V orphan pathway let iptacopan's additional benefit stand as established through EMA approval alone
- How the G-BA's 19 December 2024 finding of a substantial (beträchtlich) benefit on quality of life bypassed a head-to-head IQWiG dossier
- How Soliris, Ultomiris, Fabhalta, and Piasky differ across mechanism, company, and G-BA/AMNOG status
- Why Fabhalta's orphan-pathway approval, Piasky's pending IQWiG review, and Ultomiris's pediatric rejection define four distinct commercial positions
- Why the German PNH-Register at Ulm and the West German Cancer Center at Essen anchor the country's entire referral network
- How both German centres feed patient data into the International PNH Registry underpinning long-term eculizumab and ravulizumab outcomes
- Why the G-BA declined to require accompanying data collection for iptacopan in March 2025, citing the registry already in place
- How crovalimab's dossier, submitted 12 September 2024, remains under active IQWiG assessment while ravulizumab's 2022 pediatric review found no added benefit
- How the Ulm and Essen referral centres concentrate German PNH prescribing decisions given the disease's ultra-rare status
- Why eculizumab's long-standing incumbency meets iptacopan's proven quality-of-life benefit for patients switching from anti-C5 therapy
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (EMA, G-BA, IQWiG), peer-reviewed literature, and live German clinical-guideline documentation — not secondary summaries. Findings are independently verified before inclusion.
PNH Germany CI sources: G-BA Nutzenbewertungsverfahren decision pages for iptacopan, ravulizumab, and crovalimab; IQWiG Dossierbewertung documents; DGHO Onkopedia PNH guideline; the International PNH Registry evidence base (Kulasekararaj et al. 2025; Terriou et al. 2023); and the Orphanet German PNH-Register listing.
- AMNOG benefit-assessment dates and Beschluss categories verified against live G-BA Nutzenbewertungsverfahren pages for iptacopan, ravulizumab, and crovalimab
- German PNH epidemiology framing verified against the DGHO Onkopedia PNH guideline, which explicitly states no confirmed German-specific prevalence/incidence data exists
- German PNH-Register (Ulm) existence and contact verified via the Orphanet registry listing
- International PNH Registry outcomes data verified against Kulasekararaj et al. (Ann Hematol 2025) and Terriou et al. (Eur J Haematol 2023)
Frequently asked questions
Commission this brief
AXLRx delivers PNH competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.